Skip to main content
Signal8

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

$DWTXPress releaseApr 23, 2026, 9:00 AM ET

Dogwood Therapeutics partnered with PRIDCor to globally develop and commercialize its antiviral candidates IMC-1 and IMC-2, shifting future development and commercialization costs to the partner. Under the agreement, Dogwood is eligible for potential payments capped at $100 million, tiered royalties up to 15%, and 9% of future capital raised or milestone payments related to the assets.

Key figures

Deal Value Usd
100000000
Max royalty rate
15%
Future capital raisings share
9%
Future partnership payments share
9%

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    DWTX: Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M — AI Analysis | Signal8